Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | PIM1 | P11309 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29767032 | 1.00 | MEN1 (1.00) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL29358850 | 0.99 | MEN1 (0.98) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1559590 | 0.99 | MEN1 (0.98) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| SCHEMBL15496911 | 0.99 | MEN1 (0.98) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| SCHEMBL6106184 | 0.96 | MEN1 (0.93) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| SCHEMBL9419622 | 0.88 | PIM1 (0.78) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| SCHEMBL9419633 | 0.84 | PIM1 (0.71) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| SCHEMBL29444947 | 0.83 | MEN1 (0.71) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| SCHEMBL13305235 | 0.79 | MEN1 (0.65) | MEN1KMT2APIM1TDP1SIGMAR1 | |
| SCHEMBL6106996 | 0.76 | MEN1 (0.61) | MEN1KMT2APIM1TDP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210102165-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | claimed |
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-08 | — | — | US | claimed |
| EP-3370743-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | City of Hope (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2017079528-A9 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE (US) | 2017-06-15 | — | — | WO | claimed |
| WO-2017079528-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE (US) | 2017-05-11 | — | — | WO | claimed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| EP-4313033-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023218243-A1 | LAG-3/PD-L1 BINDING FUSION PROTEINS | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-4262878-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| EP-2524232-A2 | METHODS FOR PREDICTING RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER TO THERAPY | Nestec S.A. (CH) | 2012-11-21 | — | — | EP | disclosed |
| US-20110178076-A1 | MEDICAL INTERVENTION IN HAEMATOLOGICAL CANCERS | MEDIZINISCHE UNIVERSITAT INNSBRUCK | 2011-07-21 | — | — | US | disclosed |
| US-20110178076-A1 | MEDICAL INTERVENTION IN HAEMATOLOGICAL CANCERS | MEDIZINISCHE UNIVERSITAT INNSBRUCK | 2011-07-21 | — | — | US | disclosed |
| WO-2011088149-A2 | METHODS FOR PREDICTING RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER TO THERAPY | PROMETHEUS LABORATORIES INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2179037-A2 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | Nodality, Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009144009-A1 | MEDICAL INTERVENTION IN HAEMATOLOGICAL CANCERS | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2009-12-03 | — | — | WO | disclosed |
| US-20090142319-A1 | METHOD TO EXPAND nTREG CELLS USING PI-3K ANTAGONIST | THERAKOS, INC. | 2009-06-04 | — | — | US | disclosed |
| WO-2009025847-A2 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | MEN1 3640/4885KMT2A 1396/4885PIM1 1998/4885 |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | MEN1 1985/4885KMT2A 4040/4885PIM1 1424/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | MEN1 1985/4885KMT2A 4040/4885PIM1 1424/4885 |
| US-20110178076-A1 | MEDICAL INTERVENTION IN HAEMATOLOGICAL CANCERS | PIK3CA, PI4KB, PTEN | MEN1 207/4885KMT2A 77/4885PIM1 631/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | MEN1 4832/4885KMT2A 577/4885PIM1 2636/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | MEN1 180/4885KMT2A 1084/4885PIM1 2317/4885 |
| US-20210102165-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | MEN1 3640/4885KMT2A 1396/4885PIM1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.